Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Japan Govt to Halt R&D Tax Break for Small Spender Companies: PM Abe
January 24, 2018
- Eligibility for Conditional Early Approval “Will Not Be Restricted to Orphan Drugs”: MHLW
January 24, 2018
- Japan’s 1st Herceptin Biosimilar Likely to Be OK’ed by March for Gastric Cancer
January 23, 2018
- Shionogi’s Sakigake-Designated Flu Med Up for MHLW Panel Review on Feb. 2, Early Listing Possible?
January 23, 2018
- Cooperation from Govt, Insurers to Meet 80% Generic Target, Control of Long-Term Prescriptions Requested: Chuikyo Public Hearings
January 22, 2018
- MHLW OKs Dupixent, Tecentriq, Lynparza, and More
January 22, 2018
- PMDA to Promote Simplification of Documentation Required in Applications, Acceptance of Documents in Electronic Form
January 19, 2018
- Chuikyo OKs New Drug Pricing Rules for FY2018 Reform
January 18, 2018
- Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing
January 18, 2018
- Chuikyo OKs Special Re-Pricing for FY2018 Drug Price Revision, Here’s the List of Products
January 17, 2018
- MHLW Health Policy Chief Wants Pricing Reform to Prod Drug Makers’ Overseas Expansions
January 17, 2018
- Chuikyo Plans for FY2018 Fee Schedule Revision Now Up for Public Comments
January 15, 2018
- Novo’s Semaglutide Up for MHLW Panel Review Jan. 26 after Approval Hold
January 15, 2018
- MHLW Orders Label Revisions for Abilify, 4 Other APIs
January 12, 2018
- Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief
January 12, 2018
- MHLW Proposes Add’l Conditions for Penalty Medical Fee Cuts: Chuikyo
January 11, 2018
- Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister
January 10, 2018
- PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive
January 9, 2018
- MHLW Unofficially Notified Companies of Products Eligible for New PMP: Sources
January 9, 2018
- MHLW Study Group Approves Framework for Comprehensive Guidelines on Pharmacotherapy in the Elderly
January 9, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…